File Download
  Patent History
  • Application
    US 12/4246811 2014-04-07
  • Publication
    US 20140302070 2014-10-09
  Patent Family
Supplementary

Patent: NOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES

TitleNOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSES
Priority Date2014-04-07 US 12/4246811
2013-04-05 US 12/1808993P
Inventors
Issue Date2014
Citation
US Published patent application US 20140302070. Washington, DC: US Patent and Trademark Office (USPTO), 2014 How to Cite?
AbstractIn one embodiment, the present invention provides a new isoform of human PD1 ([Delta]42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. [Delta]42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, [Delta]42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+ T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble [Delta]42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing [Delta]42PD1 could be used as immunogens for developing antibodies binding specifically to [Delta]42PD1. In yet another embodiment, neutralizing antibodies could block s[Delta]42PD1 function and accordingly could be used as treatment for autoimmune disorders.
Persistent Identifierhttp://hdl.handle.net/10722/206633

 

DC FieldValueLanguage
dc.date.accessioned2014-11-21T08:12:24Z-
dc.date.available2014-11-21T08:12:24Z-
dc.date.issued2014en_US
dc.identifier.citationUS Published patent application US 20140302070. Washington, DC: US Patent and Trademark Office (USPTO), 2014en_US
dc.identifier.urihttp://hdl.handle.net/10722/206633-
dc.description.abstractIn one embodiment, the present invention provides a new isoform of human PD1 ([Delta]42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. [Delta]42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, [Delta]42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+ T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble [Delta]42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing [Delta]42PD1 could be used as immunogens for developing antibodies binding specifically to [Delta]42PD1. In yet another embodiment, neutralizing antibodies could block s[Delta]42PD1 function and accordingly could be used as treatment for autoimmune disorders.en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documentsen_US
dc.titleNOVEL PD1 ISOFORMS, AND USES THEREOF FOR POTENTIATING IMMUNE RESPONSESen_US
dc.typePatenten_US
dc.identifier.authorityCHEN, ZHIWEI=rp00243en_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorCHEN, ZHIWEIen_US
dc.contributor.inventorCHENG, LINen_US
dc.contributor.inventorCHEUNG, ALLEN KA LOONen_US
dc.contributor.inventorZHOU, JINGYINGen_US
patents.identifier.applicationUS 12/4246811en_US
patents.description.assigneeUNIV HONG KONG [CN]en_US
patents.description.countryUnited States of Americaen_US
patents.date.publication2014-10-09en_US
patents.identifier.hkutechidAIDS-2012-00458-1en_US
patents.date.application2014-04-07en_US
patents.date.priority2014-04-07 US 12/4246811en_US
patents.date.priority2013-04-05 US 12/1808993Pen_US
patents.description.ccusen_US
patents.identifier.publicationUS 20140302070en_US
patents.relation.familyWO 2014161509 (A1) 2014-10-09en_US
patents.description.kindA1en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats